Dragonfly Therapeutics Announces Multi-target Expansion of its Collaboration With Merck

Dragonfly Therapeutics, Inc. announced an expansion of its strategic collaboration with Merck, known as MSD outside of the United States and Canada to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease and immune disorders.